First fixed-ratio combination of insulin degludec and liraglutide for the treatment of type 2 diabetes

Marc Rendell

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

When oral hypoglycemic agents do not successfully suppress hyperglycemia, the traditional approach has been to add insulin injections. With the coming of glucagon-like peptide 1 (GLP-1) receptor agonists carrying the benefits of weight loss and reduced risk of hypoglycemia, it has been suggested that GLP-1 agents should be used instead. There is equivalent lowering of HbA1c with either treatment. Insulin therapy is associated with hypoglycemia and weight gain while GLP-1 receptor agonists promote weight loss. Gastrointestinal (GI) intolerance is the chief obstacle to GLP-1 treatment. The combined use of basal insulin and GLP-1 receptor agonists results in improved glycemic control and mitigates weight gain. The recent approval of insulin degludec/liraglutide administered in a fixed ratio combination is unique not simply for the additive benefits of the two agents, but because it now permits adjustable dosing of liraglutide together with insulin, providing better glucose control than with either agent alone at lower dose levels. Lower dosage of insulin degludec reduces the risk of hypoglycemia. Liraglutide combats the weight gain that accompanies the introduction of insulin therapy, and a reduced dose of liraglutide induces less GI intolerance. This first combined basal insulin-GLP-1 receptor agonist combination represents a conceptual advance in the treatment of insulin-requiring type 2 diabetes.

Original languageEnglish
Pages (from-to)185-196
Number of pages12
JournalDrugs of Today
Volume51
Issue number3
DOIs
StatePublished - Mar 1 2015

Fingerprint

Type 2 Diabetes Mellitus
Insulin
Hypoglycemia
Weight Gain
Glucagon-Like Peptide 1
Therapeutics
Weight Loss
insulin degludec
Liraglutide
Hypoglycemic Agents
Hyperglycemia
Glucose
Injections
Glucagon-Like Peptide-1 Receptor

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Medicine(all)

Cite this

First fixed-ratio combination of insulin degludec and liraglutide for the treatment of type 2 diabetes. / Rendell, Marc.

In: Drugs of Today, Vol. 51, No. 3, 01.03.2015, p. 185-196.

Research output: Contribution to journalArticle

@article{9be4fbf00c0d4f8e82015d36eb995afb,
title = "First fixed-ratio combination of insulin degludec and liraglutide for the treatment of type 2 diabetes",
abstract = "When oral hypoglycemic agents do not successfully suppress hyperglycemia, the traditional approach has been to add insulin injections. With the coming of glucagon-like peptide 1 (GLP-1) receptor agonists carrying the benefits of weight loss and reduced risk of hypoglycemia, it has been suggested that GLP-1 agents should be used instead. There is equivalent lowering of HbA1c with either treatment. Insulin therapy is associated with hypoglycemia and weight gain while GLP-1 receptor agonists promote weight loss. Gastrointestinal (GI) intolerance is the chief obstacle to GLP-1 treatment. The combined use of basal insulin and GLP-1 receptor agonists results in improved glycemic control and mitigates weight gain. The recent approval of insulin degludec/liraglutide administered in a fixed ratio combination is unique not simply for the additive benefits of the two agents, but because it now permits adjustable dosing of liraglutide together with insulin, providing better glucose control than with either agent alone at lower dose levels. Lower dosage of insulin degludec reduces the risk of hypoglycemia. Liraglutide combats the weight gain that accompanies the introduction of insulin therapy, and a reduced dose of liraglutide induces less GI intolerance. This first combined basal insulin-GLP-1 receptor agonist combination represents a conceptual advance in the treatment of insulin-requiring type 2 diabetes.",
author = "Marc Rendell",
year = "2015",
month = "3",
day = "1",
doi = "10.1358/dot.2015.51.3.2294596",
language = "English",
volume = "51",
pages = "185--196",
journal = "Drugs of Today",
issn = "0025-7656",
publisher = "Prous Science",
number = "3",

}

TY - JOUR

T1 - First fixed-ratio combination of insulin degludec and liraglutide for the treatment of type 2 diabetes

AU - Rendell, Marc

PY - 2015/3/1

Y1 - 2015/3/1

N2 - When oral hypoglycemic agents do not successfully suppress hyperglycemia, the traditional approach has been to add insulin injections. With the coming of glucagon-like peptide 1 (GLP-1) receptor agonists carrying the benefits of weight loss and reduced risk of hypoglycemia, it has been suggested that GLP-1 agents should be used instead. There is equivalent lowering of HbA1c with either treatment. Insulin therapy is associated with hypoglycemia and weight gain while GLP-1 receptor agonists promote weight loss. Gastrointestinal (GI) intolerance is the chief obstacle to GLP-1 treatment. The combined use of basal insulin and GLP-1 receptor agonists results in improved glycemic control and mitigates weight gain. The recent approval of insulin degludec/liraglutide administered in a fixed ratio combination is unique not simply for the additive benefits of the two agents, but because it now permits adjustable dosing of liraglutide together with insulin, providing better glucose control than with either agent alone at lower dose levels. Lower dosage of insulin degludec reduces the risk of hypoglycemia. Liraglutide combats the weight gain that accompanies the introduction of insulin therapy, and a reduced dose of liraglutide induces less GI intolerance. This first combined basal insulin-GLP-1 receptor agonist combination represents a conceptual advance in the treatment of insulin-requiring type 2 diabetes.

AB - When oral hypoglycemic agents do not successfully suppress hyperglycemia, the traditional approach has been to add insulin injections. With the coming of glucagon-like peptide 1 (GLP-1) receptor agonists carrying the benefits of weight loss and reduced risk of hypoglycemia, it has been suggested that GLP-1 agents should be used instead. There is equivalent lowering of HbA1c with either treatment. Insulin therapy is associated with hypoglycemia and weight gain while GLP-1 receptor agonists promote weight loss. Gastrointestinal (GI) intolerance is the chief obstacle to GLP-1 treatment. The combined use of basal insulin and GLP-1 receptor agonists results in improved glycemic control and mitigates weight gain. The recent approval of insulin degludec/liraglutide administered in a fixed ratio combination is unique not simply for the additive benefits of the two agents, but because it now permits adjustable dosing of liraglutide together with insulin, providing better glucose control than with either agent alone at lower dose levels. Lower dosage of insulin degludec reduces the risk of hypoglycemia. Liraglutide combats the weight gain that accompanies the introduction of insulin therapy, and a reduced dose of liraglutide induces less GI intolerance. This first combined basal insulin-GLP-1 receptor agonist combination represents a conceptual advance in the treatment of insulin-requiring type 2 diabetes.

UR - http://www.scopus.com/inward/record.url?scp=84927724944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927724944&partnerID=8YFLogxK

U2 - 10.1358/dot.2015.51.3.2294596

DO - 10.1358/dot.2015.51.3.2294596

M3 - Article

VL - 51

SP - 185

EP - 196

JO - Drugs of Today

JF - Drugs of Today

SN - 0025-7656

IS - 3

ER -